Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
Michela Guglieri,Kate Bushby,Michael P McDermott,Kimberly A Hart,Rabi Tawil,William B Martens,Barbara E Herr,Elaine McColl,Chris Speed,Jennifer Wilkinson,Janbernd Kirschner,Wendy M King,Michelle Eagle,Mary W Brown,Tracey Willis,Robert C Griggs,FOR-DMD Investigators of the Muscle Study Group,Volker Straub,Henriette van Ruiten,Anne-Marie Childs,Emma Ciafaloni,Perry B Shieh,Stefan Spinty,Lorenzo Maggi,Giovanni Baranello,Russell J Butterfield,I A Horrocks,Helen Roper,Zoya Alhaswani,Kevin M Flanigan,Nancy L Kuntz,Adnan Manzur,Basil T Darras,Peter B Kang,Leslie Morrison,Monika Krzesniak-Swinarska,Jean K Mah,Tiziana E Mongini,Federica Ricci,Maja von der Hagen,Richard S Finkel,Kathleen O'Reardon,Matthew Wicklund,Ashutosh Kumar,Craig M McDonald,Jay J Han,Nanette Joyce,Erik K Henricson,Ulrike Schara-Schmidt,Andrea Gangfuss,Ekkehard Wilichowski,Richard J Barohn,Jeffrey M Statland,Craig Campbell,Giuseppe Vita,Gian Luca Vita,James F Howard Jr,Imelda Hughes,Hugh J McMillan,Elena Pegoraro,Luca Bello,W Bryan Burnette,Mathula Thangarajh,Taeun Chang
DOI: https://doi.org/10.1001/jama.2022.4315
IF: 11.816
2022-04-19
JAMA
Abstract:Importance: Corticosteroids improve strength and function in boys with Duchenne muscular dystrophy. However, there is uncertainty regarding the optimum regimen and dosage. Objective: To compare efficacy and adverse effects of the 3 most frequently prescribed corticosteroid regimens in boys with Duchenne muscular dystrophy. Design, setting, and participants: Double-blind, parallel-group randomized clinical trial including 196 boys aged 4 to 7 years with Duchenne muscular dystrophy who had not previously been treated with corticosteroids; enrollment occurred between January 30, 2013, and September 17, 2016, at 32 clinic sites in 5 countries. The boys were assessed for 3 years (last participant visit on October 16, 2019). Interventions: Participants were randomized to daily prednisone (0.75 mg/kg) (n = 65), daily deflazacort (0.90 mg/kg) (n = 65), or intermittent prednisone (0.75 mg/kg for 10 days on and then 10 days off) (n = 66). Main outcomes and measures: The global primary outcome comprised 3 end points: rise from the floor velocity (in rise/seconds), forced vital capacity (in liters), and participant or parent global satisfaction with treatment measured by the Treatment Satisfaction Questionnaire for Medication (TSQM; score range, 0 to 100), each averaged across all study visits after baseline. Pairwise group comparisons used a Bonferroni-adjusted significance level of .017. Results: Among the 196 boys randomized (mean age, 5.8 years [SD, 1.0 years]), 164 (84%) completed the trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P < .001 for daily prednisone vs intermittent prednisone using a global test; P = .017 for daily deflazacort vs intermittent prednisone using a global test) and the daily regimens did not differ significantly (P = .38 for daily prednisone vs daily deflazacort using a global test). The between-group differences were principally attributable to rise from the floor velocity (0.06 rise/s [98.3% CI, 0.03 to 0.08 rise/s] for daily prednisone vs intermittent prednisone [P = .003]; 0.06 rise/s [98.3% CI, 0.03 to 0.09 rise/s] for daily deflazacort vs intermittent prednisone [P = .017]; and -0.004 rise/s [98.3% CI, -0.03 to 0.02 rise/s] for daily prednisone vs daily deflazacort [P = .75]). The pairwise comparisons for forced vital capacity and TSQM global satisfaction subscale score were not statistically significant. The most common adverse events were abnormal behavior (22 [34%] in the daily prednisone group, 25 [38%] in the daily deflazacort group, and 24 [36%] in the intermittent prednisone group), upper respiratory tract infection (24 [37%], 19 [29%], and 24 [36%], respectively), and vomiting (19 [29%], 17 [26%], and 15 [23%]). Conclusions and relevance: Among patients with Duchenne muscular dystrophy, treatment with daily prednisone or daily deflazacort, compared with intermittent prednisone alternating 10 days on and 10 days off, resulted in significant improvement over 3 years in a composite outcome comprising measures of motor function, pulmonary function, and satisfaction with treatment; there was no significant difference between the 2 daily corticosteroid regimens. The findings support the use of a daily corticosteroid regimen over the intermittent prednisone regimen tested in this study as initial treatment for boys with Duchenne muscular dystrophy. Trial registration: ClinicalTrials.gov Identifier: NCT01603407.